Kupando GmbH

Schönefeld, DE · 2 known investors

Kupando develops dual TLR4/7 agonist therapies, particularly KUP101, to treat solid tumors and infectious diseases including antimicrobial-resistant infections. The company's approach harnesses innate immune activation and trained immunity to address cancer and infectious disease indications.

AI & Machine LearningBiotech